Invention Grant
- Patent Title: Gamma 9 delta 2 T cell receptors
-
Application No.: US14388675Application Date: 2013-03-28
-
Publication No.: US09891211B2Publication Date: 2018-02-13
- Inventor: Jürgen Herbert Ernst Kuball , Elsa-Cordula Gründer
- Applicant: UMC UTRECHT Holding B.V.
- Applicant Address: NL Utrecht
- Assignee: Gadeta B.V.
- Current Assignee: Gadeta B.V.
- Current Assignee Address: NL Utrecht
- Agency: Wilson Sonsini Goodrich & Rosati
- International Application: PCT/NL2013/050235 WO 20130328
- International Announcement: WO2013/147606 WO 20131003
- Main IPC: C07K14/705
- IPC: C07K14/705 ; G01N33/50 ; C12N15/85 ; G01N33/68 ; A61K38/00 ; A61K35/17 ; C07K14/725

Abstract:
The current invention provides methods to identify γ9δ2T-cell receptors (γ9δ2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the γ9-T-cell receptor chain and the δ2-T-Cell receptor chain (δ2TCR chain) are of importance. Based on these findings, combinatorial-γδTCR-chain-exchange (CTE) is proposed as an efficient method for identifying γ9δ2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective γ9TCR and δ2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific γ9δ2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the γ9δ2TCRs according to the invention.
Public/Granted literature
- US09546998B2 Gamma 9 delta 2 T cell receptors Public/Granted day:2017-01-17
Information query